Efungumab is under investigation in clinical trial NCT00217815 (Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Efungumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Efungumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Efungumab. |
| Estrone | Estrone may increase the thrombogenic activities of Efungumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Efungumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Efungumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Efungumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Efungumab. |
| Estriol | Estriol may increase the thrombogenic activities of Efungumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Efungumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Efungumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Efungumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Efungumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Efungumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Efungumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Efungumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Efungumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Efungumab. |
| Equol | Equol may increase the thrombogenic activities of Efungumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Efungumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Efungumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Efungumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Efungumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Efungumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Efungumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Efungumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Efungumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Efungumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Efungumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Efungumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Efungumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Efungumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Efungumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Efungumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Efungumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Efungumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Efungumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Efungumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Efungumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Efungumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Efungumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Efungumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Efungumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Efungumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Efungumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Efungumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Efungumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Efungumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Efungumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Efungumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Efungumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Efungumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Efungumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Efungumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Efungumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Efungumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Efungumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Efungumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Efungumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Efungumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Efungumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Efungumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Efungumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Efungumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Efungumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Efungumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Efungumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Efungumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Efungumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Efungumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Efungumab. |
| Hepatitis B immune globulin | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Efungumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Efungumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Efungumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Efungumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Efungumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Efungumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Efungumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Efungumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Efungumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Efungumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Efungumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Efungumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Efungumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Efungumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Efungumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Efungumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Efungumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Efungumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Efungumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Efungumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Efungumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Efungumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Efungumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Efungumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Efungumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Efungumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Efungumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Efungumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Efungumab. |